Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509585 · ClinicalTrials.gov registry record · Phase 2
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
A Phase 2 study, sponsored by Cardinal Health 414.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02509585 is a Phase 2 study that was terminated before completion, run by Cardinal Health 414. The registered enrollment target is 18 participants.
The verdict
NCT02509585, a Phase 2 study, was terminated before completion, sponsored by Cardinal Health 414.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.
Interventions
- DRUG Tc99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509585
The ClinicalTrials.gov registry entry for NCT02509585 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardinal Health 414, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc99m tilmanocept is the first listed.
NCT02509585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509585 about?
NCT02509585 is a clinical study titled "A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection". Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.
What is the current status of trial NCT02509585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-01. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02509585?
The interventions under investigation include: Tc99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT02509585?
This trial is sponsored by Cardinal Health 414, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.